KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) vs KPV (Lys-Pro-Val)

KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV)

This product is a blend of four research peptides, GHK-Cu, TB-500, BPC-157 and KPV, supplied together in one preparation. GHK-Cu is a copper-bound tripeptide first isolated from human plasma; TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ from the actin-binding region of thymosin β4; BPC-157 is a 15-residue synthetic peptide derived from a sequence in a gastric juice protein; and KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Each component has been studied on its own, mostly in cell culture and animal models. No published work has examined the four in combination, and data on their chemical stability together are lacking, so the blend has no literature of its own.

KPV (Lys-Pro-Val)

KPV is the tripeptide lysine–proline–valine, corresponding to the last three residues of alpha-melanocyte-stimulating hormone (α-MSH). It lacks the His-Phe-Arg-Trp core sequence through which α-MSH activates melanocortin receptors, so its pharmacology cannot be assumed to match that of the parent hormone. Interest in it follows reports that C-terminal fragments of α-MSH alter inflammatory signalling in cell and animal models. Published studies are mainly in cultured epithelial and immune cells and in mouse models of chemically induced colitis. The literature is small, and human data are scarce.

How KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) acts

There is no described mechanism for the four-part blend, only separate observations on its components, made in separate models. GHK-Cu is a high-affinity copper complex that has been examined in fibroblast culture. TB-500 copies the central actin-binding motif of thymosin β4, a protein that sequesters monomeric actin. BPC-157 has been examined in rodent studies of nitric oxide and VEGF receptor signalling without a settled target. KPV has been reported in cell lines to lower NF-κB activation, possibly after uptake through the PepT1 transporter. No study has asked whether these peptides interact chemically or biologically when combined, so no joint action can be described.

How KPV (Lys-Pro-Val) acts

How KPV acts has not been settled. Cell studies have reported that it lowers activation of the transcription factor NF-κB and reduces expression of inflammatory cytokines in intestinal epithelial and immune cell lines. In intestinal epithelial cells, uptake through the di- and tripeptide transporter PepT1 has been reported, which would allow it to act inside the cell rather than at a surface receptor. Whether it also signals through melanocortin receptors such as MC1R is disputed, since reports differ and its sequence lacks the usual receptor-binding motif. The mechanistic work is limited and comes largely from cell and rodent models.

The records side by side

• Type: KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV), Four-peptide blend; KPV (Lys-Pro-Val), Tripeptide (alpha-MSH fragment)

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.